Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease

Afek Kodesh, Eli Lev, Dorit Leshem-Lev, Alejandro Solodky, Ran Kornowski, Leor Perl

    Research output: Contribution to journalArticlepeer-review


    Purpose: Calcium channel blockers (CCBs) do not reduce the risk of initial or recurrent myocardial infarction (MI) in patients diagnosed with stable coronary artery disease (CAD). The aim of this current study was to evaluate the association between CCBs and aspirin resistance in patients with CAD. Methods: Patients with stable CAD who were regularly taking aspirin (75–100 mg qd) for at least 1 month prior to enrollment in the study were included. The VerifyNow system was used for platelet function testing with high on-aspirin platelet reactivity (HAPR) defined as aspirin reaction units (ARU) >550. We compared patients treated with CCBs versus control group. Results: Five hundred three patients with CAD were included in this study, and 88 were treated with CCBs. Mean age (67.9±9.7 in the CCB group vs. 66.5±11.4 in the control group), gender (77.3 male vs. 82.9%), rates of diabetes mellitus (34.7 vs. 36.9%), rates of CKD (23.5 vs. 23.5%), dyslipidemia (85.1 vs. 85.3%), and statin therapy (89.5 vs. 90.7%) were similar. The mean ARU was 465.4±70.0 for patients treated with CCBs versus 445.2±60.0 in controls (p=0.006). Similarly, 15.9% of CCB patients demonstrated HAPR compared to 7.0% (p=0.006). The administration of CCBs was independently associated with HAPR in a multivariate analysis (OR 1.72, 95% CI: 1.04–8.91, p=0.047) as well as in propensity score matched analysis (OR 1.56; CI: 1.22–1.93; p<0.001). Conclusions: Usage of CCBs is positively correlated with aspirin resistance. These findings may suggest an adverse pharmacologic effect of CCBs among patients with stable CAD treated with aspirin.

    Original languageEnglish
    Pages (from-to)467-473
    Number of pages7
    JournalCardiovascular Drugs and Therapy
    Issue number3
    StatePublished - 1 Jun 2022


    • Acute coronary syndrome
    • Calcium channel blockers
    • Coronary artery disease
    • High on-aspirin platelet reactivity

    ASJC Scopus subject areas

    • Pharmacology
    • Cardiology and Cardiovascular Medicine
    • Pharmacology (medical)


    Dive into the research topics of 'Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease'. Together they form a unique fingerprint.

    Cite this